Menu
← Oncology Approval Tracker
FDA DECISION ·
Bortezomib Injection (Maia)
bortezomib · Maia Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
An intravenous bortezomib injection product for adults with multiple myeloma or mantle cell lymphoma.
LAMPGEN ANALYSIS
Why it matters
The decision adds an IV presentation for two established hematology indications.
What research teams should watch
Keep the route and dose volume explicit to distinguish this product from formulations with other labeled administration options.
PRIMARY RECORDS